Phase I Clinical Trial of PCV24 in Children Aged 2 Months (Minimum 6 Weeks) to 17 Years
Phase I Clinical Trial Protocol of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV24) to Evaluate the Safety and Immunogenicity in Children Aged 2 Months (Minimum 6 Weeks) to 17 Years
Sponsor: Shaanxi Provincial Center for Disease Control and Prevention
Listed as NCT06675032, this PHASE1 trial focuses on Pneumococcal Infectious Disease and remains ongoing. Sponsored by Shaanxi Provincial Center for Disease Control and Prevention, it has been updated 2 times since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
2 versions recorded-
Jan 2026 — Present [monthly]
Active Not Recruiting PHASE1
Status: Enrolling By Invitation → Active Not Recruiting
-
Dec 2024 — Jan 2026 [monthly]
Enrolling By Invitation PHASE1
First recorded
Apr 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Shaanxi Provincial Center for Disease Control and Prevention
- Shanghai Reinovax Biologics Co.,LTD
For direct contact, visit the study record on ClinicalTrials.gov .